Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency

Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Baillière's best practice & research. Clinical gastroenterology 2001-06, Vol.15 (3), p.477-486
1. Verfasser: DiMagno, Eugene P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 486
container_issue 3
container_start_page 477
container_title Baillière's best practice & research. Clinical gastroenterology
container_volume 15
creator DiMagno, Eugene P.
description Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.
doi_str_mv 10.1053/bega.2001.0195
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70926534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691801901957</els_id><sourcerecordid>70926534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</originalsourceid><addsrcrecordid>eNp1kMFLwzAUh4Mobk6vHqUnb615SZM1Rxk6hYEgeg5Z8iKRra1JO9x_b-sGnjy9B-_7_eB9hFwDLYAKfrfGD1MwSqGgoMQJmYLgLAcF8nTcGeRSQTUhFyl90gGTSp2TCUBJuSjplLwuTepisJmxwWWpb9uIKYWmzkztsi6i6bZYd1njs4Q7jJjhd2NjqDFrTW3H-xAOdeq9DzZgbfeX5MybTcKr45yR98eHt8VTvnpZPi_uV7ktuejyUiFw4Z1kTqIthfLMVY56CTivOJtThZKBpVIxzszaC68clMC4ZKicr_iM3B5629h89Zg6vQ3J4mZjamz6pIcGJgUvB7A4gDY2KUX0uo1ha-JeA9WjRT1a1KNFPVocAjfH5n69RfeHH7UNQHUAcPhvFzDq9Ps7uhDRdto14b_uH0higUc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70926534</pqid></control><display><type>article</type><title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>DiMagno, Eugene P.</creator><creatorcontrib>DiMagno, Eugene P.</creatorcontrib><description>Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1053/bega.2001.0195</identifier><identifier>PMID: 11403540</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Anti-Ulcer Agents - therapeutic use ; chronic pancreatitis ; cystic fibrosis ; exocrine pancreatic insufficiency ; Exocrine Pancreatic Insufficiency - drug therapy ; Gastric Acid - physiology ; H2-receptor inhibitors ; Humans ; lipase ; lipolytic activity ; malabsorption ; Pancreas - drug effects ; Pancreas - pathology ; pancreatic enzymes ; proton pump inhibitors ; steatorrhoea</subject><ispartof>Baillière's best practice &amp; research. Clinical gastroenterology, 2001-06, Vol.15 (3), p.477-486</ispartof><rights>2001 Harcourt Publishers Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</citedby><cites>FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/bega.2001.0195$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11403540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DiMagno, Eugene P.</creatorcontrib><title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</title><title>Baillière's best practice &amp; research. Clinical gastroenterology</title><addtitle>Best Pract Res Clin Gastroenterol</addtitle><description>Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.</description><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>chronic pancreatitis</subject><subject>cystic fibrosis</subject><subject>exocrine pancreatic insufficiency</subject><subject>Exocrine Pancreatic Insufficiency - drug therapy</subject><subject>Gastric Acid - physiology</subject><subject>H2-receptor inhibitors</subject><subject>Humans</subject><subject>lipase</subject><subject>lipolytic activity</subject><subject>malabsorption</subject><subject>Pancreas - drug effects</subject><subject>Pancreas - pathology</subject><subject>pancreatic enzymes</subject><subject>proton pump inhibitors</subject><subject>steatorrhoea</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFLwzAUh4Mobk6vHqUnb615SZM1Rxk6hYEgeg5Z8iKRra1JO9x_b-sGnjy9B-_7_eB9hFwDLYAKfrfGD1MwSqGgoMQJmYLgLAcF8nTcGeRSQTUhFyl90gGTSp2TCUBJuSjplLwuTepisJmxwWWpb9uIKYWmzkztsi6i6bZYd1njs4Q7jJjhd2NjqDFrTW3H-xAOdeq9DzZgbfeX5MybTcKr45yR98eHt8VTvnpZPi_uV7ktuejyUiFw4Z1kTqIthfLMVY56CTivOJtThZKBpVIxzszaC68clMC4ZKicr_iM3B5629h89Zg6vQ3J4mZjamz6pIcGJgUvB7A4gDY2KUX0uo1ha-JeA9WjRT1a1KNFPVocAjfH5n69RfeHH7UNQHUAcPhvFzDq9Ps7uhDRdto14b_uH0higUc</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>DiMagno, Eugene P.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010601</creationdate><title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</title><author>DiMagno, Eugene P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>chronic pancreatitis</topic><topic>cystic fibrosis</topic><topic>exocrine pancreatic insufficiency</topic><topic>Exocrine Pancreatic Insufficiency - drug therapy</topic><topic>Gastric Acid - physiology</topic><topic>H2-receptor inhibitors</topic><topic>Humans</topic><topic>lipase</topic><topic>lipolytic activity</topic><topic>malabsorption</topic><topic>Pancreas - drug effects</topic><topic>Pancreas - pathology</topic><topic>pancreatic enzymes</topic><topic>proton pump inhibitors</topic><topic>steatorrhoea</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DiMagno, Eugene P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Baillière's best practice &amp; research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DiMagno, Eugene P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</atitle><jtitle>Baillière's best practice &amp; research. Clinical gastroenterology</jtitle><addtitle>Best Pract Res Clin Gastroenterol</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>15</volume><issue>3</issue><spage>477</spage><epage>486</epage><pages>477-486</pages><issn>1521-6918</issn><eissn>1532-1916</eissn><abstract>Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>11403540</pmid><doi>10.1053/bega.2001.0195</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1521-6918
ispartof Baillière's best practice & research. Clinical gastroenterology, 2001-06, Vol.15 (3), p.477-486
issn 1521-6918
1532-1916
language eng
recordid cdi_proquest_miscellaneous_70926534
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Anti-Ulcer Agents - therapeutic use
chronic pancreatitis
cystic fibrosis
exocrine pancreatic insufficiency
Exocrine Pancreatic Insufficiency - drug therapy
Gastric Acid - physiology
H2-receptor inhibitors
Humans
lipase
lipolytic activity
malabsorption
Pancreas - drug effects
Pancreas - pathology
pancreatic enzymes
proton pump inhibitors
steatorrhoea
title Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A40%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20acid%20suppression%20and%20treatment%20of%20severe%20exocrine%20pancreatic%20insufficiency&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=DiMagno,%20Eugene%20P.&rft.date=2001-06-01&rft.volume=15&rft.issue=3&rft.spage=477&rft.epage=486&rft.pages=477-486&rft.issn=1521-6918&rft.eissn=1532-1916&rft_id=info:doi/10.1053/bega.2001.0195&rft_dat=%3Cproquest_cross%3E70926534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70926534&rft_id=info:pmid/11403540&rft_els_id=S1521691801901957&rfr_iscdi=true